SCHEMBL3249037

SCHEMBL3249037

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(-c4csc(Nc5ccc(Cl)c(Cl)c5)n4)cc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.43
VCP P55072 1/20 0.43
DHODH Q02127 3/20 0.42
JAK2 O60674 2/20 0.40
JAK3 P52333 2/20 0.40
CFTR P13569 2/20 0.40
ABL1 P00519 1/20 0.40
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 3/20 0.38
PRMT5 O14744 2/20 0.38
WDR77 Q9BQA1 2/20 0.38
MEN1 O00255 2/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
RAB9A P51151 1/20 0.38
PARP1 P09874 1/20 0.38
EPHA2 P29317 1/20 0.38
KDR P35968 1/20 0.38
EPHB4 P54760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245553 0.89 ALDH1A1 (0.43) DHODHJAK2JAK3MAPTALDH1A1
SCHEMBL3253176 0.89 MEN1 (0.44) ALOX5DHODHJAK2JAK3CFTR
SCHEMBL3249507 0.88 CSNK2A2 (0.48) ALOX5VCPCFTRABL1MAPT
SCHEMBL3252671 0.88 ALOX5 (0.42) ALOX5VCPDHODHCFTRABL1
SCHEMBL3241923 0.88 MAPT (0.53) DHODHJAK2JAK3MAPTALDH1A1
SCHEMBL3251297 0.84 MEN1 (0.43) JAK2JAK3MAPTALDH1A1KMT2A
SCHEMBL3251009 0.83 PARP1 (0.47) JAK2JAK3MAPTPARP1SMN1; SMN2
SCHEMBL3254695 0.82 ABL1 (0.46) ABL1MAPTALDH1A1KMT2AMEN1
SCHEMBL3249681 0.82 PARP1 (0.44) JAK2JAK3MAPTALDH1A1KMT2A
SCHEMBL4167032 0.81 ALOX5 (0.44) ALOX5VCPCFTRABL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALOX5 2899/4885VCP 3103/4885DHODH 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.